Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 3484.

https://doi.org/10.1182/blood-2024-200317

Published: 2024

Journal Articles

Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

Ioulia Mavrikou, Daniela Taurino, Tasoula Touloumenidou, Zoi Bousiou, Evaggelia-Evdoxia Koravou, Anna Vardi, Apostolia Papalexandri, Christos Demosthenous, Maria Koutra, Alkistis Kyra Panteliadou, Ioannis Batsis, Evangelia Yannaki, Dimitrios Chatzidimitriou, Emmanouil Nikolousis, Alessandro Rambaldi, Ioanna Sakellari, Eleni Gavriilaki

Blood (2024) 144 (Supplement 1): 4778.

https://doi.org/10.1182/blood-2024-194728

Published: 2024

Journal Articles

Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Blood (2024) 144 (Supplement 1): 2194.

https://doi.org/10.1182/blood-2024-200152

Published: 2024

Journal Articles

Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis

Eleni Gavriilaki, Despina Mallouri, Ioannis Batsis, Zoi Bousiou, Anna Vardi, Nikolaos Spyridis, Georgios Karavalakis, Alkistis Kyra Panteliadou, Panagiotis Dolgyras, Christos Varelas, Vlasios I Alevizopoulos, Panagiotis Asteris, Panayiotis Vlachoyiannopoulos, Evangelia Yannaki, Damianos Sotiropoulos, Ioanna Sakellari

Blood (2024) 144 (Supplement 1): 1163.

https://doi.org/10.1182/blood-2024-199262

Published: 2024

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Leves Are Significantly Associated with Edothelial Injury Indices in Adult Allogenic Hematopoietic Cell Transplantation Recipients

Eleni Gavriilaki, Zoi Bousiou, Ioannis Batsis, Anna Vardi, Despina Mallouri, Evdoxia Koravou, Georgia Konstantinidou, Nikolaos Spyridis, Georgios Karavalakis, Vasileios Patriarcheas, Marianna Masmanidou, Tasoula Touloumenidou, Apostolia Papalexandri, Christos Poziopoulos, Evangelia Yannaki, Ioanna Sakellari, Marianna Politou, Ioannis Papassotiriou

Blood (2023) 142 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2023-178241

Published: 2023

Journal Articles

Improvement in Iron Burden in Patients with Transfusion-Dependent β-Thalassemia (TDT) Treated with Betibeglogene Autotemcel (Beti-cel) Gene Therapy: Up to 9 Years of Follow-up

Blood (2023) 142 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2023-173869

Published: 2023

Journal Articles

Sustained Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent β-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel)

Blood (2023) 142 (Supplement 1): 1102.

https://doi.org/10.1182/blood-2023-174068

Published: 2023

Journal Articles

In vivo HSC prime editing rescues sickle cell disease in a mouse model

Chang Li, Aphrodite Georgakopoulou, Gregory A. Newby, Peter J. Chen, Kelcee A. Everette, Kiriaki Paschoudi, Efthymia Vlachaki, Sucheol Gil, Anna K. Anderson, Theodore Koob, Lishan Huang, Hongjie Wang, Hans-Peter Kiem, David R. Liu, Evangelia Yannaki, André Lieber

Blood (2023) 141 (17): 2085–2099.

https://doi.org/10.1182/blood.2022018252

Published: 2023

Includes: Supplemental data

Journal Articles

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Cellular Therapies: A Real-World Analysis

Eleni Gavriilaki, Panagiotis Dolgyras, Sotiria Dimou-Mpesikli, Aikaterini Poulopoulou, Christos Demosthenous, Evangelia Zachrou, Panagiotis Siasios, Despina Mallouri, Anna Vardi, Zoi Bousiou, Alkistis Panteliadou, Marianna Masmanidou, Chrysavgi Lalayanni, Evangelia Yannaki, Damianos Sotiropoulos, Achilles Anagnostopoulos, Timoleon Achilleas Vyzantiadis, Ioanna Sakellari

Blood (2022) 140 (Supplement 1): 4790–4791.

https://doi.org/10.1182/blood-2022-156570

Published: 2022

Journal Articles

Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials

Blood (2022) 140 (Supplement 1): 5355–5357.

https://doi.org/10.1182/blood-2022-162400

Published: 2022

Journal Articles

Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia

Franco Locatelli, Mark C. Walters, Janet L. Kwiatkowski, Marina Cavazzana, Suradej Hongeng, John B. Porter, Adrian J. Thrasher, Andreas E. Kulozik, Isabelle Thuret, John E.J. Rasko, Evangelia Yannaki, Martin G. Sauer, Shamshad Ali, Himal Thakar, Katiana Gruppioni, Alexis A. Thompson

Blood (2022) 140 (Supplement 1): 8200–8202.

https://doi.org/10.1182/blood-2022-163178

Published: 2022

Journal Articles

Chronic Graft-Versus-Host Disease Immunoprofiling Reveals T Cell Clonal Dynamics That Correlate with Disease Activity: A Novel Molecular "Biomarker"?

Anna Vardi, Elisavet Vlachonikola, Dimitra Gkouvelou, Evdoxia Koravou, Electra Sofou, Sofia Gkagkaridou, Maria Karipidou, Panagiota Zerva, Christos Demosthenous, Asimina Fylaktou, Ioannis Batsis, Apostolia Papalexandri, Anastasia Papadopoulou, Evangelia Yannaki, Ioanna Sakellari, Kostas Stamatopoulos, Achilles Anagnostopoulos, Anastasia Chatzidimitriou

Blood (2021) 138 (Supplement 1): 3811.

https://doi.org/10.1182/blood-2021-150424

Published: 2021

Journal Articles

Humoral and T Cell Immune Responses to Sars-Cov-2 Vaccination in Hematopoietic Cell Transplant Recipients

Eleni Gavriilaki, Anastasia Papadopoulou, Tasoula Touloumenidou, Fani Stavridou, Evdoxia Koravou, Maria Giannaki, Apostolia Papalexandri, Georgios Karavalakis, Ioannis Batsis, Andreas Kourelis, Fani Chatzopoulou, Dimitrios Chatzidimitriou, Damianos Sotiropoulos, Evangelia Yannaki, Ioanna Sakellari, Achilles Anagnostopoulos

Blood (2021) 138 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2021-149399

Published: 2021

Journal Articles

Improvement in Health-Related Quality of Life Following Treatment with Betibeglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia Enrolled in Phase 3 Studies

Janet L. Kwiatkowski, Franco Locatelli, Mark C. Walters, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Richard A. Colvin, Katiana Gruppioni, Alexis A. Thompson

Blood (2021) 138 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2021-150392

Published: 2021

Journal Articles

Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up

Alexis A. Thompson, Franco Locatelli, Evangelia Yannaki, Mark C. Walters, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Marina Cavazzana, John E.J. Rasko, Lin Du, Richard A. Colvin, Janet L. Kwiatkowski

Blood (2021) 138 (Supplement 1): 573.

https://doi.org/10.1182/blood-2021-148177

Published: 2021

Journal Articles

Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34 + cells in vitro and in vivo

Nikoletta Psatha, Aphrodite Georgakopoulou, Chang Li, Vivek Nandakumar, Grigorios Georgolopoulos, Reyes Acosta, Kiriaki Paschoudi, Jemma Nelson, Daniel Chee, Anastasia Athanasiadou, Anastasia Kouvatsi, Alister Peter William Funnell, André Lieber, Evangelia Yannaki, Thalia Papayannopoulou

Blood (2021) 138 (17): 1540–1553.

https://doi.org/10.1182/blood.2020010020

Published: 2021

Includes: Supplemental data

Journal Articles

In Vivo HSC Gene Therapy for Hemoglobinopathies: A Proof of Concept Evaluation in Rhesus Macaques

Chang Li, Hongjie Wang, PhD, Sucheol Gil, Afrodite Georgakopoulou, PhDstudent, Stefan Radtke, PhD, Evangelia Yannaki, MD, Thalia Papayannopoulou, MD DrSci, Hans-Peter Kiem, MDPhD, Andre Lieber, MD PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-141468

Published: 2020

Journal Articles

Response of Patients with Transfusion-Dependent β-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers

Mark C. Walters, MD, David H.K. Chui, MD FRCPC, John J Farrell, PhD, Ashutosh Lal, MD, Franco Locatelli, MD PhD, Janet L. Kwiatkowski, MD MSCE, John B. Porter, MA, MD, FRCP, FRCPath, Martin G. Sauer, MD, Isabelle Thuret, MD, Suradej Hongeng, MD, Andreas E. Kulozik, MD PhD, Adrian J. Thrasher, MBBS, PhD FMedSci, Evangelia Yannaki, MD, Julia Yang, Dustin Whitney, PhD, Alexandria Petrusich, Richard A. Colvin, MD PhD, Alexis A. Thompson, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-137642

Published: 2020

Journal Articles

Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes

Apostolia Papalexandri, MD, Eleni Gavriilaki, MD, Anna Vardi, MD PhD, Eirini Baldoumi, Christos Demosthenous, MD, Natasa Konstantinou, MD, Tasoula Touloumenidou, Panagiota Zerva, Fotini Kika, Angeliki Paleta, Michalis Iskas, Ioannis Batsis, Despina Mallouri, Evangelia Yannaki, MD, Ioanna Sakellari, MDPhD, Achilles Anagnostopoulos

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-141596

Published: 2020

Journal Articles

Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia

Alexis A. Thompson, MD, Janet L. Kwiatkowski, MD MSCE, John B. Porter, MA, MD, FRCP, FRCPath, Suradej Hongeng, MD, Evangelia Yannaki, MD, Andreas E. Kulozik, MD PhD, Martin G. Sauer, MD, Adrian J. Thrasher, MBBS, PhD FMedSci, Isabelle Thuret, MD, Ashutosh Lal, MD, Ruiting Guo, MS, Weijian Liu, PhD, Richard A. Colvin, MD PhD, Mark C. Walters, MD, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 52–54.

https://doi.org/10.1182/blood-2020-135857

Published: 2020

NARROW

Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation

Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Leves Are Significantly Associated with Edothelial Injury Indices in Adult Allogenic Hematopoietic Cell Transplantation Recipients

Improvement in Iron Burden in Patients with Transfusion-Dependent β-Thalassemia (TDT) Treated with Betibeglogene Autotemcel (Beti-cel) Gene Therapy: Up to 9 Years of Follow-up

Sustained Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent β-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel)

In vivo HSC prime editing rescues sickle cell disease in a mouse model

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Cellular Therapies: A Real-World Analysis

Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials

Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia

Chronic Graft-Versus-Host Disease Immunoprofiling Reveals T Cell Clonal Dynamics That Correlate with Disease Activity: A Novel Molecular "Biomarker"?

Humoral and T Cell Immune Responses to Sars-Cov-2 Vaccination in Hematopoietic Cell Transplant Recipients

Improvement in Health-Related Quality of Life Following Treatment with Betibeglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia Enrolled in Phase 3 Studies

Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up

Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34 + cells in vitro and in vivo

In Vivo HSC Gene Therapy for Hemoglobinopathies: A Proof of Concept Evaluation in Rhesus Macaques

Response of Patients with Transfusion-Dependent β-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers

Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes

Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only